

Refine Search

Search Results -

Terms	Documents
L6 and L1	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L8

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, October 01, 2005 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=PGPB,USPT; PLUR=YES; OP=OR

<u>L8</u>	L6 and l1	1	<u>L8</u>
<u>L7</u>	L6 and l3	1	<u>L7</u>
<u>L6</u>	L5 and l4	13	<u>L6</u>
<u>L5</u>	byun.in.	506	<u>L5</u>
<u>L4</u>	yang.in.	15338	<u>L4</u>

DB=USPT; PLUR=YES; OP=OR

<u>L3</u>	L2 and protamine	1707	<u>L3</u>
<u>L2</u>	heparin inactivation	41989	<u>L2</u>
<u>L1</u>	purified protamine and heparin	216565	<u>L1</u>

END OF SEARCH HISTORY

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 6624141 B1

Using default format because multiple data bases are involved.

L8: Entry 1 of 1

File: USPT

Sep 23, 2003

US-PAT-NO: 6624141

DOCUMENT-IDENTIFIER: US 6624141 B1

**** See image for Certificate of Correction ****

TITLE: Protamine fragment compositions and methods of use

DATE-ISSUED: September 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Yang</u> ; Victor C.	Ann Arbor	MI		
<u>Byun</u> ; Youngro	Kwangsang-Ku Kwangju			KR

US-CL-CURRENT: 514/2; 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KIMC	Draw Desc	Ima
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------	-----

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms	Documents
L6 and L1	1

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Welcome to STN International! Enter x:x

PASSWORD:

* * * * * Welcome to STN International * * * * *

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * STN Columbus * * * * *

```
=> file medline, biosis, wpids, uspatful, biotechds, fsta, embase, dgene
COST IN U.S. DOLLARS                               SINCE FILE          TOTAL
```

FILE 'BIOSIS' ENTERED AT 10:19:15 ON 01 OCT 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 10:19:15 ON 01 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHDS' ENTERED AT 10:19:15 ON 01 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 10:19:15 ON 01 OCT 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'EMBASE' ENTERED AT 10:19:15 ON 01 OCT 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 10:19:15 ON 01 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> s protamine and heparin
L1 8662 PROTAMINE AND HEPARIN

=> s l1 and (heparin inactivation)
L2 6 L1 AND (HEPARIN INACTIVATION)

=> d l2 ti abs ibib tot

L2 ANSWER 1 OF 6 MEDLINE on STN
TI [Amino acid composition, heterogeneity and antiheparin activity of
protamine sulfate from the milt roe of the sturgeon *Acipenser*
sturio].
Aminokislотноyi sostav, geterogennost' i antieparinovaia aktivnost'
protamina sul'fata molok osetra *Acipenser sturio*.
AB The homogeneous preparation of **protamine** sulphate is obtained
chromatographically and electrophoretically from milt roe of the sturgeon.
Its amino acid composition and properties are studied. The methods to
blockade the functional groups of **protamine** sulphate amino acids
is used to investigate the possible mechanism of **heparin**
inactivation.
ACCESSION NUMBER: 90208925 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2631325
TITLE: [Amino acid composition, heterogeneity and antiheparin
activity of **protamine** sulfate from the milt roe
of the sturgeon *Acipenser sturio*].
Aminokislотноyi sostav, geterogennost' i antieparinovaia
aktivnost' protamina sul'fata molok osetra *Acipenser*
sturio.
AUTHOR: Borodinskaia I N; Mishunin I F
SOURCE: Ukrainskii biokhimicheskii zhurnal, (1989 Nov-Dec) 61 (6)
84-8.
Journal code: 7804246. ISSN: 0201-8470.
PUB. COUNTRY: USSR
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Russian
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199005
ENTRY DATE: Entered STN: 19900601
Last Updated on STN: 19900601
Entered Medline: 19900502

L2 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI AMINO ACID COMPOSITION HETEROGENEITY AND ANTIHEPARIN ACTIVITY OF
PROTAMINE SULFATE FROM STURGEON MILT ROE ACIPENSER-STURIO.
AB The homogeneous preparation of **protamine** sulphate is obtained
chromatographically and electrophoretically from milt roe of the sturgeon.
Its amino acid composition and properties are studied. The methods of
blockade the functional groups of **protamine** sulphate amino acids
is used to investigate the possible mechanism of **heparin**

inactivation.

ACCESSION NUMBER: 1990:136075 BIOSIS
DOCUMENT NUMBER: PREV199089074886; BA89:74886
TITLE: AMINO ACID COMPOSITION HETEROGENEITY AND ANTIHEPARIN
ACTIVITY OF **PROTAMINE** SULFATE FROM STURGEON MILT
ROE ACIPENSER-STURIO.
AUTHOR(S): BORODINSKAYA I N [Reprint author]; MISHUNIN I F
CORPORATE SOURCE: AV PALLADIN INST BIOCHEM, ACAD SCI UKR SSR, KIEV, USSR
SOURCE: Ukrainskii Biokhimicheskii Zhurnal, (1989) Vol. 61, No. 6,
pp. 84-88.
CODEN: UBZHD4. ISSN: 0201-8470.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: RUSSIAN
ENTRY DATE: Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990

L2 ANSWER 3 OF 6 USPATFULL on STN

TI Coated surfaces for immobilizing negatively charged anticoagulating
agents from blood fluid

AB A wound closure apparatus is provided which utilizes blood fluid by
activating the clotting cascade of blood fluid outside the body within a
substantially enclosed sterile container then introducing, the blood
fluid to the wound site to complete clotting. An apparatus for providing
ways of inhibiting anticoagulating agents, and slowing fibrin clot
degradation are also disclosed. Kits for practicing the invention
singularly or in combination with, and/or associated with preferred
procedures are also disclosed. The invention provides a clotting cascade
initiation apparatus (1) including a substantially enclosed sterile
containment chamber within which an aliquot of blood fluid, either
autologous or from donor sources can be received, and retained. In
preferred embodiments, the sterile containment chamber further includes
a **heparin** binding agent which will bind **heparin** and
remove it from the blood fluid. In further embodiments, the containment
chamber will also include a procoagulating agent, wherein a clotting
cascade can be initiated when the blood fluid is accepted into the
sterile containment chamber.

ACCESSION NUMBER: 2003:325393 USPATFULL
TITLE: Coated surfaces for immobilizing negatively charged
anticoagulating agents from blood fluid
INVENTOR(S): Sandhu, Shivpal S., Reading, UNITED KINGDOM
PATENT ASSIGNEE(S): BioInteractions Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003229376	A1	20031211
APPLICATION INFO.:	US 2003-389696	A1	20030314 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-291965, filed on 12 Nov 2002, PENDING Continuation of Ser. No. US 2002-194403, filed on 11 Jul 2002, PENDING Continuation of Ser. No. US 2000-585488, filed on 1 Jun 2000, GRANTED, Pat. No. US 6482223		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-136837P	19990601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Brad Pedersen, Patterson, Thunte, Skaar & Christensen, P.A., 4800 IDS Center, 80 South 8th Street, Minneapolis, MN, 55402-2100	
NUMBER OF CLAIMS:	15	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 992

L2 ANSWER 4 OF 6 USPATFULL on STN

TI Clotting cascade initiating apparatus and methods of use
AB Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anti-coagulating agents and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed. The present invention provides improved methods of creating hemostasis or control of bleeding at the site of wounds, particularly wounds created in arteries during procedures employing percutaneous access. The invention preferably includes the steps of acquiring an aliquot of a patient's blood, i.e., autologous blood, removing a negatively charged anti-coagulating agent, preferably **heparin**, from the blood, and preferably initiating the blood's natural clotting cascades and transporting the thus treated blood to the site of the wound where the clotting cascade will be completed producing a clot at the wound site that will create a condition of hemostasis. The invention further provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a **heparin** binding agent which will bind **heparin** and remove it from the blood fluid. In further embodiments the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.

ACCESSION NUMBER: 2003:100490 USPATFULL
TITLE: Clotting cascade initiating apparatus and methods of use
INVENTOR(S): Nowakowski, Karol L., Circle Pines, MN, UNITED STATES
Olson, James E., Eagan, MN, UNITED STATES
Joseph, Edward T., Inver Grove Heights, MN, UNITED STATES
Ericson, Daniel G., Rochester, MN, UNITED STATES
PATENT ASSIGNEE(S): Closys Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069601	A1	20030410
APPLICATION INFO.:	US 2002-291965	A1	20021112 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-585488, filed on 1 Jun 2000, GRANTED, Pat. No. US 6482223 Continuation-in-part of Ser. No. US 1998-212080, filed on 15 Dec 1998, GRANTED, Pat. No. US 6159232		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Robert C. Freed, MOORE & HANSEN, 2900 Wells Fargo Center, 90 South Seventh Street, Minneapolis, MN, 55402		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	1102		

L2 ANSWER 5 OF 6 USPATFULL on STN

TI Clotting cascade initiating apparatus and methods of use

AB Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anti-coagulating agents and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed. The present invention provides improved methods of creating hemostasis or control of bleeding at the site of wounds, particularly wounds created in arteries during procedures employing percutaneous access. The invention preferably includes the steps of acquiring an aliquot of a patient's blood, i.e., autologous blood, removing a negatively charged anti-coagulating agent, preferably **heparin**, from the blood, and preferably initiating the blood's natural clotting cascades and transporting the thus treated blood to the site of the wound where the clotting cascade will be completed producing a clot at the wound site that will create a condition of hemostasis. The invention further provides a clotting cascade initiation apparatus including a substantially enclosed sterile containment chamber within which an aliquot of blood fluid, either autologous or from donor sources, can be received and retained. In preferred embodiments, the sterile containment chamber further includes a **heparin** binding agent which will bind **heparin** and remove it from the blood fluid. In further embodiments the containment chamber will also include a procoagulating agent, wherein a clotting cascade can be initiated when the blood fluid is accepted into the sterile containment chamber.

ACCESSION NUMBER: 2002:303578 USPATFULL
TITLE: Clotting cascade initiating apparatus and methods of use
INVENTOR(S): Nowakowski, Karol L., Circle Pines, MN, United States
Olson, James E., Eagan, MN, United States
Joseph, Edward T., Inver Grove Heights, MN, United States
Ericson, Daniel G., Rochester, MN, United States
PATENT ASSIGNEE(S): Closys Corporation, Edina, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6482223	B1	20021119
APPLICATION INFO.:	US 2000-585488		20000601 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-212080, filed on 15 Dec 1998, now patented, Pat. No. US 6159232		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69834P	19971216 (60)
	US 1999-136837P	19990601 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Jackson, Gary	
LEGAL REPRESENTATIVE:	Moore & Hansen	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1095	

L2 ANSWER 6 OF 6 USPATFULL on STN

TI Process and device for the specific adsorption of **heparin**

AB A process for the specific adsorption of **heparin** and other **heparin**-like substances which comprises flowing a buffered

solution of whole blood, from which corpuscular blood constituents have been removed, plasma and/or solutions containing whole blood or plasma through an adsorber capsule containing a medium that adsorbs **heparin** and other **heparin**-like substances at an acid pH, preferably in the range of 4.0 to 5.5. Preferably, the process is carried out in a closed, extracorporeal circulation and the medium possesses anion exchange resin properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 90:48589 USPATFULL

TITLE: Process and device for the specific adsorption of **heparin**

INVENTOR(S): Seidel, Dietrich, Gottingen, Germany, Federal Republic of
Feller, Wolfgang, Melsungen, Germany, Federal Republic of
Roskopf, Gerhard, Fuldabruck-Dornhagen, Germany, Federal Republic of

PATENT ASSIGNEE(S): B. Braun-SSC AG, Emmenbrucke, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4935204		19900619
APPLICATION INFO.:	US 1988-271368		19881114 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-149905, filed on 28 Jan 1988, now abandoned which is a continuation of Ser. No. US 1985-744197, filed on 13 Jun 1985, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1984-3422494	19840616
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rollins, John W.	
LEGAL REPRESENTATIVE:	Kenyon & Kenyon	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	798	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e yang, v/au

E1	1	YANG ZX/AU
E2	14	YANG ZY/AU
E3	0 -->	YANG, V/AU
E4	3	YANGA/AU
E5	1	YANGA C S/AU
E6	8	YANGA D/AU
E7	1	YANGA F/AU
E8	1	YANGA F C/AU
E9	1	YANGA FENG/AU
E10	17	YANGA K/AU
E11	3	YANGA KIDIAMENE/AU
E12	3	YANGA M D/AU

=> e byun, y/au

E1	2	BYUN YOUNGSUP/AU
E2	3	BYUN YU CHAN/AU
E3	0 -->	BYUN, Y/AU
E4	1	BYUNAU E/AU
E5	8	BYUNAU E K/AU

E6 1 BYUNG A H LEE/AU
E7 2 BYUNG B L/AU
E8 2 BYUNG BUM CHOI/AU
E9 2 BYUNG C C/AU
E10 2 BYUNG C J/AU
E11 1 BYUNG C K/AU
E12 2 BYUNG C L/AU

=> d his

(FILE 'HOME' ENTERED AT 10:16:31 ON 01 OCT 2005)

FILE 'MEDLINE, BIOSIS, WPIDS, USPATFULL, BIOTECHDS, FSTA, EMBASE, DGENE'
ENTERED AT 10:19:15 ON 01 OCT 2005

L1 8662 S PROTAMINE AND HEPARIN
L2 6 S L1 AND (HEPARIN INACTIVATION)
E YANG, V/AU
E BYUN, Y/AU

=> s l1 and bleeding disorder

L3 128 L1 AND BLEEDING DISORDER

=> s l2 and l3

L4 0 L2 AND L3